LeukoTreat aims at developing therapeutic strategies for leukodystrophy (LD) affected patients

LeukoTreat is a European project funded by the European Commission under the 7th Framework Programme for Research and Development. It aims at developing therapeutic strategies for the largest number of leukodystrophy (LD) affected patients as well as the development of further applications to more common white matter disorders and neurodegenerative diseases.

LeukoTreat is a collaborative project gathering 24 partners among which:

• 16 public research laboratories with the most skilled European Researchers in the field of LDs;
• A biopharmaceutical SME (Trophos) committed to the discovery and development of innovative therapeutics for neurological, cardiac and hepatic diseases;
• A SME (Soluscience) skilled in the development of computer tools;
• A laboratory (Laboratoire d’Ethique Médicale, LEM) skilled in research in ethics;
• The European Leukodystrophy Association, ELA which supports patients suffering from LDs and their families;
• A SME (France Europe Innovation) skilled in the administrative and financial management of European collaborative projects.

The project began on March 1st 2010 and will last 3 years.

• Scientific coordination: Odile Boespflug-Tanguy, Université Paris Diderot - Paris 7
• Administrative, legal and financial coordination: Delphine Chatard and Olivier Degrand, France Europe Innovation

Project Results obtained at Month 18

This document presents main results obtained within the project at this stage:

The survey launched by the LeukoTreat Ethics Committee is now closed. This survey aimed at evaluating expectations of patients and their families regarding research and thereby at improving information level and providing better support.

                                                     Analysis of results gathered is currently undergoing.

                                             For information purpose, surveys models can still be downloaded.

                                     You can also read our Information Sheet, available in English and in French.